These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 35212571

  • 1. A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup.
    Kawa SM, Stroomberg HV, Larsen SB, Helgstrand JT, Toft BG, Vickers AJ, Brasso K, Røder MA.
    J Urol; 2022 Jul; 208(1):100-108. PubMed ID: 35212571
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO.
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [Abstract] [Full Text] [Related]

  • 5. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L.
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [Abstract] [Full Text] [Related]

  • 6. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [Abstract] [Full Text] [Related]

  • 7. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP, Lantto J, Pääkkö E, Piippo U, Kauppila S, Lammentausta E, Ohtonen P, Vaarala MH.
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [Abstract] [Full Text] [Related]

  • 8. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [Abstract] [Full Text] [Related]

  • 9. Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies.
    Nafie S, Pal RP, Dormer JP, Khan MA.
    World J Urol; 2014 Aug; 32(4):971-5. PubMed ID: 24337167
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, Gielens MPM, van der Linden H, Beerlage HP, de Reijke TM, Wijkstra H, Roobol MJ.
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [Abstract] [Full Text] [Related]

  • 13. The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy.
    Nafie S, Wanis M, Khan M.
    Urol J; 2017 Mar 16; 14(2):3008-3012. PubMed ID: 28299763
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH, Roethke MC, Seidenader J, Simpfendörfer T, Boxler S, Alammar K, Rieker P, Popeneciu VI, Roth W, Pahernik S, Schlemmer HP, Hohenfellner M, Hadaschik BA.
    J Urol; 2013 Oct 16; 190(4):1380-6. PubMed ID: 23608676
    [Abstract] [Full Text] [Related]

  • 16. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
    Lai WJ, Wang HK, Liu HT, Park BK, Shen SH, Lin TP, Chung HJ, Huang YH, Chang YH.
    J Chin Med Assoc; 2016 Nov 16; 79(11):618-624. PubMed ID: 27567440
    [Abstract] [Full Text] [Related]

  • 17. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Boesen L, Nørgaard N, Løgager V, Balslev I, Thomsen HS.
    Urol Int; 2017 Nov 16; 99(4):384-391. PubMed ID: 28651247
    [Abstract] [Full Text] [Related]

  • 18. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
    Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E, Gabbert HE, Becker N, Antoch G, Albers P, Schimmöller L.
    Eur Urol; 2015 Oct 16; 68(4):713-20. PubMed ID: 26116294
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
    Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, PROMIS study group.
    Lancet; 2017 Feb 25; 389(10071):815-822. PubMed ID: 28110982
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.